Loading...
XNAS
ANIK
Market cap217mUSD
Jul 09, Last price  
16.09USD
1D
-1.53%
1Q
9.01%
Jan 2017
-67.14%
Name

Anika Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ANIK chart
P/E
P/S
1.90
EPS
Div Yield, %
Shrs. gr., 5y
0.16%
Rev. gr., 5y
-2.86%
Revenues
113m
-5.91%
26,840,61430,829,82135,779,78740,135,70455,556,59464,778,63571,358,50575,081,154105,594,83992,999,000103,379,000113,420,000105,555,000114,610,000130,457,000147,794,000113,827,000120,792,000119,907,000112,819,000
Net income
-11m
L-80.70%
4,604,2166,035,2543,629,1953,687,5674,315,9958,466,68011,757,46020,574,52138,319,47930,758,00032,547,00031,816,00018,722,00027,193,000-23,982,0004,134,000-14,859,000-82,667,000-56,385,000-10,880,000
CFO
11m
+107.07%
2,001,1724,492,6423,407,2313,094,7057,853,46110,173,13410,548,67725,165,00039,978,37539,064,00023,801,00040,812,00034,918,00037,005,00013,065,0008,397,0004,409,000-1,788,0005,403,00011,188,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
IPO date
May 16, 1985
Employees
345
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT